Zymeworks BC Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-10-21: Study NCT07164313; Company role Lead sponsor; Phase Phase 1; Status Recruiting.
- 2024-10-30: Study NCT06555744; Company role Lead sponsor; Phase Phase 1; Status Active not recruiting.
- 2024-09-30: Study NCT06523803; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2024-07-18: Study NCT05615818; Company role Collaborator; Phase Phase 3; Status Recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-10-21 | NCT07164313 A Study of ZW251 in Participants With Advanced Solid Tumors | Lead sponsor | Phase 1 | Recruiting | Hepatocellular Carcinoma; Squamous Cell Non-Small Cell Lung Cancer; Germ Cell Tumor | 100 | 2028-05 |
| 2024-10-30 | NCT06555744 A Study of ZW191 in Participants With Solid Tumors | Lead sponsor | Phase 1 | Active not recruiting | Advanced Solid Tumors | 145 | 2027-01 |
| 2024-09-30 | NCT06523803 A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers | Lead sponsor | Phase 1 | Terminated | Mesothelin-expressing Advanced Cancers | 32 | 2025-10-01 |
| 2024-07-18 | NCT05615818 Personalized Medicine for Advanced Biliary Cancer Patients | Collaborator Lead: UNICANCER | Phase 3 | Recruiting | Biliary Tract Neoplasms | 800 | 2028-06 |
| 2021-11-16 | NCT05035836 A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Recruiting | Breast Cancer; HER2-positive | 20 | 2028-12-29 |
| 2020-08-12 | NCT04513665 ZW25 in Women With Endometrial Cancers | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Phase 2 | Completed Results posted | Endometrial Cancer; Carcinosarcoma | 16 | 2024-03-08 |
| 2019-04-15 | NCT03821233 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | Lead sponsor | Phase 1 | Completed | HER2-expressing Cancers | 112 | 2024-10-08 |